Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Diego Novick, Sae Young Lee, Dong Hyun Koo, Agota Szende & Sam Colman. (2022) Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. Journal of Drug Assessment 11:1, pages 12-19.
Read now
Read now
Karinna Saxby, Carolyn Nickson, G Bruce Mann, Allan Park, Hannah Bromley, Louiza Velentzis, Pietro Procopio, Karen Canfell & Dennis Petrie. (2021) Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 847-857.
Read now
Read now
Articles from other publishers (18)
Huai-liang Wu, Zi-yin Luo, Zong-lin He, Yue Gong, Miao Mo, Wai-kit Ming & Guang-yu Liu. (2022) All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits. British Journal of Cancer 128:4, pages 638-646.
Crossref
Crossref
Rana El Haidari, Amelie Anota, Tienhan S. Dabakuyo-Yonli, Francis Guillemin, Thierry Conroy, Michel Velten, Damien Jolly, Sylvain Causeret, Jean Cuisenier, Olivier Graesslin, Linda Abou Abbas & Virginie Nerich. (2022) Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments. Quality of Life Research 31:10, pages 3077-3085.
Crossref
Crossref
Manraj N. Kaur, Jiajun Yan, Anne F. Klassen, Justin P. David, Dilshan Pieris, Manraj Sharma, Louise Bordeleau & Feng Xie. (2022) A Systematic Literature Review of Health Utility Values in Breast Cancer. Medical Decision Making 42:5, pages 704-719.
Crossref
Crossref
Katherine A. Hrebinko, Cindy L. Bryce, Stephanie Downs‐Canner, Emilia J. Diego & Sara P. Myers. (2022) Cost‐effectiveness of Choosing Wisely guidelines for axillary observation in women older than age 70 years with hormone receptor–positive, clinically node‐negative, operable breast tumors. Cancer 128:12, pages 2258-2268.
Crossref
Crossref
Seon-Ha Kim, Minsu Ock, Min-Woo Jo & Sungchan Park. (2022) Estimation of Utility Weights for Prostate-related Health States in Korea. Journal of Preventive Medicine and Public Health 55:3, pages 243-252.
Crossref
Crossref
Jerry Zeng Yang Wong, Jia Hui Chai, Yen Shing Yeoh, Nur Khaliesah Mohamed Riza, Jenny Liu, Yik-Ying Teo, Hwee Lin Wee & Mikael Hartman. (2021) Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore. BMC Health Services Research 21:1.
Crossref
Crossref
Mir-Masoud Pourrahmat, Ashley Kim, Anuraag R. Kansal, Marg Hux, Divya Pushkarna, Mir Sohail Fazeli & Karen C. Chung. (2021) Health state utility values by cancer stage: a systematic literature review. The European Journal of Health Economics 22:8, pages 1275-1288.
Crossref
Crossref
Sarocha Chootipongchaivat, Xin Yi Wong, Kevin ten Haaf, Mikael Hartman, Kelvin B. Tan, Nicolien T. van Ravesteyn & Hwee-Lin Wee. (2021) Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study. Cancer Epidemiology, Biomarkers & Prevention 30:4, pages 653-660.
Crossref
Crossref
Jiryoun Gong, Juhee Han, Donghwan Lee & Seungjin Bae. (2020) A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients’ Experience. International Journal of Environmental Research and Public Health 17:24, pages 9412.
Crossref
Crossref
Qing Yang, Xuexin Yu & Wei Zhang. (2020) Health variations among breast-cancer patients from different disease states: evidence from China. BMC Health Services Research 20:1.
Crossref
Crossref
Annie M. Q. Wang, Helene Retrouvey, Murray Krahn, Steven J. McCabe & Heather L. Baltzer. (2020) Direct and indirect utilities of patients with mild to moderate versus severe carpal tunnel syndrome. Journal of Hand Surgery (European Volume) 45:8, pages 832-837.
Crossref
Crossref
Tzu-Chun Chou, Shao-Chin Chiang & Yu Ko. (2020) Health state utilities for metastatic breast cancer in Taiwan. The Breast 51, pages 57-64.
Crossref
Crossref
Hannah L. Bromley, G. Bruce Mann, Dennis Petrie, Carolyn Nickson, Daniel Rea & Tracy E. Roberts. (2019) Valuing preferences for treating screen detected ductal carcinoma in situ. European Journal of Cancer 123, pages 130-137.
Crossref
Crossref
Lin Li, J. L. (Hans) Severens & Olena Mandrik. (2019) Disutility associated with cancer screening programs: A systematic review. PLOS ONE 14:7, pages e0220148.
Crossref
Crossref
Alexander Y. Yoon, Laura Bozzuto, Andrew J. Seto, Carla S. Fisher & Abhishek Chatterjee. (2019) A Systematic Review of Utility Score Assessments in the Breast Surgery Cost-Analysis Literature. Annals of Surgical Oncology 26:5, pages 1190-1201.
Crossref
Crossref
Hannah L. Bromley, Dennis Petrie, G.Bruce Mann, Carolyn Nickson, Daniel Rea & Tracy E. Roberts. (2019) Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures. Social Science & Medicine 228, pages 142-154.
Crossref
Crossref
Eun-Jung Kim, Minsu Ock, Kyu-pyo Kim, Nuri Hyun Jung, Hyeon-Jeong Lee, Seon-Ha Kim & Min-Woo Jo. (2018) Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea. BMC Cancer 18:1.
Crossref
Crossref
Le Wang, Ju-Fang Shi, Juan Zhu, Hui-Yao Huang, Ya-Na Bai, Guo-Xiang Liu, Xian-Zhen Liao, A-Yan Mao, Jian-Song Ren, Xiao-Jie Sun, Lan-Wei Guo, Yi Fang, Qi Zhou, Heng-Min Ma, Xiao-Jing Xing, Lin Zhu, Bing-Bing Song, Ling-Bin Du, Ling Mai, Yu-Qin Liu, Ying Ren, Li Lan, Jin-Yi Zhou, Xiao Qi, Xiao-Hua Sun, Pei-An Lou, Shou-Ling Wu, Ni Li, Kai Zhang, Jie He & Min Dai. (2018) Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey. The Breast 39, pages 53-62.
Crossref
Crossref